DZ2376A1 - Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. - Google Patents

Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Info

Publication number
DZ2376A1
DZ2376A1 DZ970226A DZ970226A DZ2376A1 DZ 2376 A1 DZ2376 A1 DZ 2376A1 DZ 970226 A DZ970226 A DZ 970226A DZ 970226 A DZ970226 A DZ 970226A DZ 2376 A1 DZ2376 A1 DZ 2376A1
Authority
DZ
Algeria
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
sulfonamide derivatives
derivatives process
Prior art date
Application number
DZ970226A
Other languages
English (en)
Inventor
Steven Mark Bromidge
Francis David King
Paul Adrian Wyman
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626377.7A external-priority patent/GB9626377D0/en
Priority claimed from GBGB9700901.3A external-priority patent/GB9700901D0/en
Priority claimed from GBGB9722757.3A external-priority patent/GB9722757D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ2376A1 publication Critical patent/DZ2376A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DZ970226A 1996-12-19 1997-12-07 Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. DZ2376A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9626377.7A GB9626377D0 (en) 1996-12-19 1996-12-19 Novel compounds
GBGB9700901.3A GB9700901D0 (en) 1997-01-17 1997-01-17 Novel compounds
GBGB9722757.3A GB9722757D0 (en) 1997-10-27 1997-10-27 Novel compounds

Publications (1)

Publication Number Publication Date
DZ2376A1 true DZ2376A1 (fr) 2002-12-28

Family

ID=27268644

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ970226A DZ2376A1 (fr) 1996-12-19 1997-12-07 Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Country Status (31)

Country Link
US (2) US6423717B1 (fr)
EP (1) EP0946539B1 (fr)
JP (1) JP2001506646A (fr)
KR (1) KR20000069554A (fr)
CN (1) CN1246116A (fr)
AP (1) AP1277A (fr)
AR (1) AR010795A1 (fr)
AT (1) ATE247099T1 (fr)
AU (1) AU729056B2 (fr)
BG (1) BG103530A (fr)
BR (1) BR9713734A (fr)
CA (1) CA2275492A1 (fr)
CZ (1) CZ220399A3 (fr)
DE (1) DE69724142T2 (fr)
DZ (1) DZ2376A1 (fr)
EA (1) EA002351B1 (fr)
ES (1) ES2203831T3 (fr)
HU (1) HUP0000658A3 (fr)
ID (1) ID22821A (fr)
IL (1) IL130297A0 (fr)
MA (1) MA24426A1 (fr)
NO (1) NO993003D0 (fr)
NZ (1) NZ335970A (fr)
OA (1) OA11066A (fr)
PE (1) PE46899A1 (fr)
PL (1) PL334337A1 (fr)
SK (1) SK80899A3 (fr)
TR (1) TR199901361T2 (fr)
TW (1) TW418205B (fr)
UY (1) UY24819A1 (fr)
WO (1) WO1998027081A1 (fr)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
EP0994862B1 (fr) 1997-07-11 2005-06-01 SmithKline Beecham plc Derives sulphonamide comme antagonistes du recepteur 5-ht6 et procede pour leur preparation
JP4253126B2 (ja) 1998-01-29 2009-04-08 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ調節剤
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
GB9818914D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
WO2001045694A1 (fr) * 1999-12-21 2001-06-28 Smithkline Beecham Corporation Antagonistes des recepteurs de l'urotensine ii
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6399617B1 (en) 2000-07-21 2002-06-04 Biovitrum Ab Use
US6818639B2 (en) 2000-07-21 2004-11-16 Biovitrum Ab Pharmaceutical combination formulation and method of treatment with the combination
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
SE0002739D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New use
US7071220B2 (en) 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
CN1245400C (zh) * 2000-09-18 2006-03-15 东亚荣养株式会社 N－取代苯并噻唑磺胺衍生物
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US6849644B2 (en) 2000-11-21 2005-02-01 Smithkline Beecham P.L.C. Isoquinoline derivatives useful in the treatment of CNS disorders
US7132546B2 (en) 2000-12-22 2006-11-07 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
EP1389194A2 (fr) * 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibiteurs de bace
WO2002090337A1 (fr) * 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
WO2002089793A1 (fr) * 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
US6743796B2 (en) 2001-05-07 2004-06-01 Wyeth Piperazinyl-isatins
WO2002089785A1 (fr) * 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
AR033879A1 (es) * 2001-05-07 2004-01-07 Smithkline Beecham Corp Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto
WO2002089740A2 (fr) * 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
GB0111186D0 (en) * 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
EP1406884A1 (fr) 2001-05-11 2004-04-14 Biovitrum Ab Composes arylsulfonamide pour le traitement de l'obesite, de diabetes de type ii et de troubles du systeme nerveux central
US7718650B2 (en) 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
RS88803A (sr) * 2001-05-11 2007-02-05 Biovitrum Ab., Nova jedinjenja arilsulfonamida za lečenje gojaznosti, dijabetesa tipa ii i poremećaja cns
BR0210929A (pt) 2001-06-07 2004-06-08 Hoffmann La Roche Derivados de indol com afinidade para o receptor 5-ht6
CN1800185A (zh) 2001-06-11 2006-07-12 比奥维特罗姆股份公司 取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ii型糖尿病的药物的应用
ES2268113T3 (es) 2001-06-15 2007-03-16 F. Hoffmann-La Roche Ag Derivados de 4-piperazinilindol con afinidad al receptor 5-ht6.
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
EP1414442A1 (fr) * 2001-08-07 2004-05-06 Smithkline Beecham Plc 3-arylsulfonyl-7-piperazinyl- indols, -benzofurans et benzothiophenes a affinite avec les recepteurs 5-ht6 pour le traitement de troubles du snc
MXPA04001250A (es) 2001-08-10 2004-05-27 Hoffmann La Roche Derivados de arilsulfonilo con afinidad receptora de 5-hidroxitriptamina6 (5-ht6).
TWI325317B (en) * 2001-09-05 2010-06-01 Eisai R&D Man Co Ltd Appetite-stimulating agents and remedies for anorexia
SE0103644D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
EP1450806B1 (fr) * 2001-11-09 2009-04-29 Biovitrum AB (publ) Utilisation de derives sulfonamide dans le traitement de l'obesite ou pour la reduction de prise d'aliments
RS44204A (sr) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
EA200400707A1 (ru) 2001-11-22 2004-10-28 Биовитрум Аб Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
MXPA04004981A (es) * 2001-11-30 2004-08-11 Hoffmann La Roche Derivados de piperazina para uso como antagonistas del receptor ccr-3 en tratamiento de asma.
AU2003244452A1 (en) * 2002-02-05 2003-09-02 Glaxo Group Limited Method of promoting neuronal growth
EP1474401A2 (fr) * 2002-02-05 2004-11-10 Novo Nordisk A/S Nouvelles aryl- et heteroarylpiperazines
ATE323680T1 (de) * 2002-02-13 2006-05-15 Glaxo Group Ltd 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen
WO2003068732A2 (fr) * 2002-02-13 2003-08-21 Glaxo Group Limited Derives benzenesulfonamide
MXPA04007920A (es) * 2002-02-13 2004-11-26 Glaxo Group Ltd Derivados de bencensulfonamida como agentes antisicoticos.
RU2309154C9 (ru) * 2002-03-27 2016-09-27 Глэксо Груп Лимитед 3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
US20040142948A1 (en) * 2002-05-07 2004-07-22 Dashyant Dhanak Sulfonamides
PT1506179E (pt) * 2002-05-13 2006-06-30 Hoffmann La Roche Derivados de benzoxazina como moduladores de 5-ht6 e suas utilizacoes
WO2004000828A1 (fr) * 2002-06-20 2003-12-31 Biovitrum Ab Composes utiles pour le traitement de l'obesite, du diabete de type ii et des troubles du systeme nerveux central
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
EP1897881A3 (fr) 2002-06-20 2009-03-18 Biovitrum AB (publ) Composés utiles pour le traitement de l'obésité, du diabète de type II et des troubles du système nerveux central
RU2324693C2 (ru) 2002-10-18 2008-05-20 Ф.Хоффманн-Ля Рош Аг 4-пиперазинилбензолсульфонилиндолы, характеризующиеся сродством к рецептору 5-нт6
AU2003295408A1 (en) * 2002-11-06 2004-06-03 Smithkline Beecham Corporation Sulfonamides
AU2003291262A1 (en) * 2002-11-06 2004-06-03 Smithkline Beecham Corporation Sulfonamides
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
US7153858B2 (en) 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds
US20060257613A1 (en) * 2003-02-13 2006-11-16 Horst Berneth Metal complexes as light-absorbing compounds in the information layer of optical data carriers
US7319111B2 (en) * 2003-02-20 2008-01-15 Encysive Pharmaceuticals, Inc. Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists
TWI289141B (en) * 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
US7262197B2 (en) * 2003-03-31 2007-08-28 Janssen Pharmaceutica, N.V Phospholipase C inhibitors for use in treating inflammatory disorders
US6946466B2 (en) * 2003-04-10 2005-09-20 Schering Ag Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
GB0320320D0 (en) * 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
AU2004299438A1 (en) * 2003-12-19 2005-06-30 Biovitrum Ab Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
PE20060574A1 (es) * 2004-07-28 2006-06-24 Glaxo Group Ltd Derivados de arilpiperazina sulfonamida como agonistas de los receptores de secretagogos de la hormona del crecimiento (ghs)
CN102114244A (zh) * 2004-09-30 2011-07-06 弗·哈夫曼-拉罗切有限公司 治疗认知障碍的组合物和方法
EP1812389B1 (fr) 2004-10-14 2011-08-17 Abbott GmbH & Co. KG Composes d'azabicycloheptyle destines au traitement des troubles reagissant a une modulation du recepteur de dopamine d<sb>3</sb>
CA2583983C (fr) * 2004-10-14 2013-07-16 Abbott Gmbh & Co. Kg Composes heterocycliques convenant pour traiter des troubles sensibles a une modulation du recepteur d3 de la dopamine
WO2006062481A1 (fr) * 2004-12-09 2006-06-15 Biovitrum Ab Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central
EP1676841A1 (fr) * 2004-12-30 2006-07-05 Esteve Laboratorios Dr. Esteve S.A. Composés substitués type sulphonamide d'indazole ou sulphonamide de 2,3-dihydroindole, leur préparation et leur utilisation comme médicaments
KR100931928B1 (ko) * 2005-01-12 2009-12-15 인제대학교 산학협력단 P25/cdk5 저해 화합물을 포함하는 퇴행성 뇌질환의 예방 및치료용 약학 조성물
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
BRPI0520579B8 (pt) 2005-08-12 2021-05-25 Suven Life Sciences Ltd composto, processo para a preparação de um composto e composição farmacêutica
KR101250820B1 (ko) 2005-08-16 2013-04-04 수벤 라이프 사이언시스 리미티드 개선된 로사르탄 제조 방법
EP1976495A2 (fr) * 2006-01-06 2008-10-08 Aarhus Universitet Composes agissant sur le transporteur de la serotonine
PE20080176A1 (es) 2006-03-31 2008-04-25 Glaxo Group Ltd Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs)
WO2007118900A1 (fr) 2006-04-19 2007-10-25 Abbott Gmbh & Co. Kg Composés hétérocycliques pouvant être utilisés pour traiter des troubles qui répondent à la modulation du récepteur de sérotonine 5ht6
BRPI0710177A2 (pt) * 2006-04-19 2012-05-29 Abbott Gmbh & Co Kg arilsulfonas heterocìclicas adequadas para tratar distúrbios que respondem à modulação do receptor 5ht6 de serotonina
EP2038256A1 (fr) 2006-05-23 2009-03-25 TransTech Pharma, Inc 6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridine et son utilisation comme medicament
EP2402324A1 (fr) 2006-05-29 2012-01-04 High Point Pharmaceuticals, LLC Benzodioxolylcyclopropylpipérazinylpyridazines
US7906555B2 (en) 2006-10-26 2011-03-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
MX2009006077A (es) 2007-01-08 2009-06-17 Suven Life Sciences Ltd Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6.
BRPI0806542A2 (pt) 2007-01-10 2014-04-22 Hoffmann La Roche Derivados de sulfonamida como inibidores de quimase
US8507469B2 (en) 2007-03-23 2013-08-13 Abbott Gmbh & Co. Kg Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
EA016594B1 (ru) 2007-05-03 2012-06-29 Сувен Лайф Сайенсиз Лимитед Производные 1-(аминоалкоксиарилсульфонил)индола в качестве 5-нтлигандов
EP2014656A3 (fr) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC Nouveaux antagonistes d'hétéocycliques h3
DE602007012683D1 (de) * 2007-07-19 2011-04-07 Esteve Labor Dr Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
US7964627B2 (en) 2007-10-26 2011-06-21 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-HT6 ligands
PA8802201A1 (es) * 2007-11-02 2009-06-23 Abbott Gmbh & Co Kg Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
EP2508177A1 (fr) 2007-12-12 2012-10-10 Glaxo Group Limited Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EP2288345B1 (fr) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Produits psycho-pharmaceutiques
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN102089278A (zh) * 2008-06-11 2011-06-08 Irm责任有限公司 用于治疗疟疾的化合物和组合物
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
CA2737282C (fr) * 2008-09-17 2014-03-25 Suven Life Sciences Limited Composes amines d'arylsulfonamide et leur utilisation en tant que ligands de 5-ht<sb>6</sb>
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
KR101073703B1 (ko) 2009-04-07 2011-10-14 한국화학연구원 피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
US8362010B2 (en) 2009-04-30 2013-01-29 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
AU2010243585B2 (en) 2009-04-30 2014-08-07 AbbVie Deutschland GmbH & Co. KG N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
WO2010125135A1 (fr) * 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg Composés de benzènesulfonanilide pour le traitement de troubles répondant à la modulation du récepteur 5-ht6 de la sérotonine
JP5628937B2 (ja) 2010-01-05 2014-11-19 スベン ライフ サイエンシズ リミティド ５−ｈｔ６受容体リガンドとしてのスルホン化合物
EP3323818A1 (fr) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
WO2012059431A1 (fr) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Composés de type benzènesulfonyle ou sulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6 de la sérotonine
WO2012059432A1 (fr) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Composés de type n-phényl-(homo)pipérazinyl-benzènesulfonyle ou benzènesulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6
ES2413911B1 (es) * 2011-12-15 2014-05-14 Universidad De Zaragoza Agente inhibidor de la agregación del peptido beta amiloide.
JP2015512383A (ja) 2012-03-20 2015-04-27 アダムド エスピー．ゼット オー．オー．Ａｄａｍｅｄ Ｓｐ．Ｚ Ｏ．Ｏ． Ｃｎｓ疾患の処置のためのベンジルアミンのスルホンアミド誘導体
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
CN105531272B (zh) 2013-07-25 2017-12-22 雅盖隆大学 作为5‑ht6拮抗剂的吡咯并喹啉衍生物、其制备方法和用途
US9840482B2 (en) 2014-04-19 2017-12-12 Sunshine Lake Pharma Co., Ltd. Sulfonamide derivatives and pharmaceutical applications thereof
CN105367472B (zh) * 2014-08-12 2020-04-21 广东东阳光药业有限公司 吲哚啉类衍生物及其在药物上的应用
CN105367473B (zh) * 2014-08-12 2020-02-11 广东东阳光药业有限公司 吲哚啉类衍生物及其在药物上的应用
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
CN108926565A (zh) * 2017-05-26 2018-12-04 中国科学院上海生命科学研究院 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
WO2019180176A1 (fr) 2018-03-21 2019-09-26 Spherium Biomed, S.L. Composition pour le traitement de la schizophrénie et/ou de la psychose
CA3102136A1 (fr) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methodes de traitement de troubles associes au recepteur s1p1<sb />
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE81861C (fr)
NZ193654A (en) * 1979-05-16 1984-08-24 Wuelfing Johann A Naphthalene sulphonamido-alkyl-piperidines,pyrrolidines or piperazines and pharmaceutical compositions
US4315014A (en) * 1980-09-24 1982-02-09 Warner-Lambert Company Antibacterial amide compounds and pharmaceutical composition containing the same
EP0076072B1 (fr) * 1981-09-24 1987-05-13 BEECHAM - WUELFING GmbH &amp; Co. KG Sulfonamides
CN85106905A (zh) * 1985-08-08 1987-02-04 Fmc公司 含有1-芳基-δ2-1，2，4，-三唑啉-5-酮类的除草剂及其制备方法
EP0462179A4 (en) * 1989-02-27 1992-03-18 The Du Pont Merck Pharmaceutical Company Novel sulfonamides as radiosensitizers
JPH04330057A (ja) * 1991-05-01 1992-11-18 Hiroyoshi Hidaka アニリンアリールスルホン酸アミド類及び薬剤として許容され得るその酸付加塩
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DE4206531A1 (de) * 1992-03-02 1993-09-09 Bayer Ag N-aryl-stickstoffheterocyclen
DE4303376A1 (de) * 1993-02-05 1994-08-11 Bayer Ag Substituierte Triazolinone
JP3328936B2 (ja) * 1993-09-03 2002-09-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ｄレセプター拮抗薬用インドールおよびインドリン誘導体
WO1995011243A1 (fr) * 1993-10-19 1995-04-27 Smithkline Beecham Plc Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d
US5801170A (en) * 1993-12-07 1998-09-01 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5HT1D antagonists
AU2565595A (en) * 1994-05-28 1995-12-21 Smithkline Beecham Plc Amide derivatives having 5ht1d-antagonist activity
US5939451A (en) 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Also Published As

Publication number Publication date
NO993003L (no) 1999-06-18
MA24426A1 (fr) 1998-07-01
AP9901556A0 (en) 1999-06-30
JP2001506646A (ja) 2001-05-22
IL130297A0 (en) 2000-06-01
ATE247099T1 (de) 2003-08-15
BG103530A (bg) 2000-01-31
NZ335970A (en) 2001-10-26
NO993003D0 (no) 1999-06-18
CZ220399A3 (cs) 1999-11-17
TW418205B (en) 2001-01-11
US6423717B1 (en) 2002-07-23
CA2275492A1 (fr) 1998-06-25
PE46899A1 (es) 1999-06-24
US20030069233A1 (en) 2003-04-10
HUP0000658A2 (hu) 2001-02-28
HUP0000658A3 (en) 2001-03-28
DE69724142D1 (de) 2003-09-18
AR010795A1 (es) 2000-07-12
WO1998027081A1 (fr) 1998-06-25
US6599904B2 (en) 2003-07-29
UY24819A1 (es) 2001-08-27
AU729056B2 (en) 2001-01-25
EA002351B1 (ru) 2002-04-25
AP1277A (en) 2004-05-05
SK80899A3 (en) 2000-02-14
PL334337A1 (en) 2000-02-28
BR9713734A (pt) 2000-03-28
ES2203831T3 (es) 2004-04-16
EP0946539A1 (fr) 1999-10-06
EP0946539B1 (fr) 2003-08-13
ID22821A (id) 1999-12-09
OA11066A (en) 2003-03-10
CN1246116A (zh) 2000-03-01
DE69724142T2 (de) 2004-06-03
TR199901361T2 (xx) 1999-08-23
AU6090498A (en) 1998-07-15
KR20000069554A (ko) 2000-11-25
EA199900561A1 (ru) 2000-02-28

Similar Documents

Publication Publication Date Title
DZ2376A1 (fr) Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DZ2457A1 (fr) Derivés de nicotinamide nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2407A1 (fr) Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2634A1 (fr) Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ2758A1 (fr) Dérivés bicycliques d0acide hydroxamique nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1957A1 (fr) Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2891A1 (fr) Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2621A1 (fr) AGonistes de prostaglandines nouveaux procédé pourleur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr) Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2666A1 (fr) Dérivés d&#39;acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation.
MA26659A1 (fr) Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2198A1 (fr) Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant.
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26432A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2718136B1 (fr) Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
DZ3042A1 (fr) Dérivés d&#39;isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2870A1 (fr) Dérivés d&#39;acide hydroxypipécolate-hydroxamique nouveaux, procédé pour leur préparation et compositi ons pharmaceutiques les contenant.
DZ2227A1 (fr) Dérivés d&#39;indole nouveaux, procédé pour leur préparation et formulations pharmaceutiques les contenant.
MA26686A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26433A1 (fr) Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2777A1 (fr) Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26558A1 (fr) Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.